SEPTERNA
Septerna is a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs).
SEPTERNA
Industry:
Biotechnology
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.septerna.com
Total Employee:
11+
Status:
Active
Contact:
650-338-3533
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
Mimecast
Similar Organizations
Faze Medicines
Faze Medicines is a biotechnology company.
Geneius
Geneius is a Biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Investors List
Invus
Invus investment in Series A - Septerna
Catalio Capital Management
Catalio Capital Management investment in Series A - Septerna
Samsara BioCapital
Samsara BioCapital investment in Series A - Septerna
Logos Capital
Logos Capital investment in Series A - Septerna
BVF Partners
BVF Partners investment in Series A - Septerna
Third Rock Ventures
Third Rock Ventures investment in Series A - Septerna
Casdin Capital
Casdin Capital investment in Series A - Septerna
Official Site Inspections
http://www.septerna.com Semrush global rank: 4.25 M Semrush visits lastest month: 2.74 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Septerna"
About Us - Septerna
Septerna is a biotechnology company powered by our proprietary Native Complex Platform ... We have built a strong values-driven organization advancing cutting-edge science and relentlessly …See details»
Septerna - Crunchbase Company Profile & Funding
Septerna is a biotechnology company that discovers and advances novel small-molecule medicines targeting G protein-coupled receptors. The company's …See details»
Septerna - LinkedIn
Septerna is on a mission to make the promise of future GPCR medicines a reality for patients. Combining the latest advances in biochemical, structural and computational drug discovery approaches ...See details»
Septerna, Inc. (SEPN) Company Profile & Facts - Yahoo Finance
See the company profile for Septerna, Inc. (SEPN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Investor FAQs - Septerna
Oct 24, 2024 Septerna is headquartered at 250 East Grand Avenue, South San Francisco, CA 94080. The main phone number is (650) 338-3533. Press space to expand and collapse this …See details»
Septerna Inc | Reuters
Oct 24, 2024 Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million. October 25, 2024 Goldman …See details»
Septerna :: HypoPARAthyroidism Association Inc.
Our mission is to discover, develop, and commercialize medicines that improve the lives of patients by combining the potential of high-value GPCR drug targets with the power of state-of …See details»
Septerna - VentureRadar
Septerna's Native Complex™ Platform is shifting the paradigm of GPCR drug discovery and bringing previously “undruggable” GPCRs into play as therapeutic targets. This creates an …See details»
Septerna
May 14, 2025 Septerna is a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors. About Us ... values-driven …See details»
Septerna - workinbiotech.com
Septerna is developing drugs against G-protein coupled receptors (GPCRs). GPCRs are found at the cell membrane and have proven to be the most ‘druggable’ class of proteins. However, …See details»
Septerna launches for new approach to targeting GPCRs
Jan 27, 2022 Septerna’s series A round will advance a pipeline of small-molecule drugs aimed at difficult-to-reach receptors, a new phase in Lefkowitz’s career after nearly 5 decades of …See details»
Mission, Vision & Core Values of Septerna
Dec 19, 2024 At Septerna, our mission, vision, and core values serve as the guiding principles that shape every aspect of our organization. With a commitment to excellence, innovation, and …See details»
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs ...
Feb 14, 2025 At Septerna, many of the 16 investors from the company’s Series A and B rounds had “very significant interest” in taking on larger positions, according to Finer. So as the IPO …See details»
Novo Doubles Down on Oral Obesity Meds With Septerna Deal
6 days ago Septerna is fresh off a $331.2 million IPO in October 2024, and the partnership adds to that windfall. The biotech launched in 2022 on the back of a $100 million series A funding, …See details»
Press Releases - Septerna
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein …See details»
Septerna - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Septerna . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of Board …See details»
Careers - Septerna
We are a strong, values-driven organization advancing cutting-edge science and relentlessly focused on developing a portfolio of impactful new medicines for patients with significant …See details»
Septerna Expands Leadership with Appointment of Industry …
Jan 6, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G …See details»
Septerna Highlights Business Progress and Reports First Quarter …
5 days ago Septerna anticipates initiating a Phase 1 clinical trial to assess safety, tolerability, PK, and pharmacodynamics (through an icatibant skin challenge) of SEP-631 in healthy …See details»
Pipeline - Septerna
Sep 30, 2024 We are advancing a wholly owned portfolio of oral small molecule GPCR-targeted programs focused initially on treating patients with significant unmet needs in endocrinology, …See details»